Skip to main content

04-03-2017 | Melanoma | Article

Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial

Schreuer M et al. Lancet Oncol 2017; 18(4): 464-472. doi:10.1016/S1470-2045(17)30171-7

Please log in to get access to this content

Related topics